Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C5H6NO3.Mg |
| Molecular Weight | 280.5171 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]2CCC(=O)N2
InChI
InChIKey=JQAACYUZYRBHGG-QHTZZOMLSA-L
InChI=1S/2C5H7NO3.Mg/c2*7-4-2-1-3(6-4)5(8)9;/h2*3H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*3-;/m00./s1
| Molecular Formula | Mg |
| Molecular Weight | 24.305 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H6NO3 |
| Molecular Weight | 128.106 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htmCurator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Sources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htm
Curator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated
NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3271 |
|||
Target ID: P02452|||Q15176|||Q9UML6 Gene ID: 1277.0 Gene Symbol: COL1A1 Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL2111421 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel Approved UseLange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne. Launch Date1.34256958E12 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | EcoCare™ Zinclean Approved UseUse in anti-dandruff shampoos |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Chromosome 13 dementia syndromes as models of neurodegeneration. | 2001 Dec |
|
| Inhibition of a model protease--pyroglutamate aminopeptidase by a natural oligosaccharide gum from Hakea gibbosa. | 2001 Jan 16 |
|
| In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles. | 2001 Mar |
|
| Comparison of the positive and negative ion electrospray mass spectra of some small peptides containing pyroglutamate. | 2002 |
|
| Continuous spectrometric assays for glutaminyl cyclase activity. | 2002 Apr 1 |
|
| Major outer membrane proteins and proteolytic processing of RgpA and Kgp of Porphyromonas gingivalis W50. | 2002 Apr 1 |
|
| Stereoselective synthesis of dipeptide beta-turn mimetics: 7-benzyl and 8-phenyl substituted azabicyclo[4.3.0]nonane amino acid esters. | 2002 Sep 6 |
|
| Pressure/temperature combined treatments of precursors yield hormone-like peptides with pyroglutamate at the N terminus. | 2003 Dec 31 |
|
| Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana. | 2003 Feb 28 |
|
| Pyrrolidinones derived from (S)-pyroglutamic acid: penmacric acid and analogues. | 2003 Jul 7 |
|
| [Characteristics of pyrrolidone pharmacokinetics in rats]. | 2003 Nov-Dec |
|
| Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. | 2004 Apr 9 |
|
| Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis. | 2004 Feb |
|
| Stabilization of peptide guinea pig myelin basic protein 72-85 by N-terminal acetylation-implications for immunological studies. | 2004 Feb |
|
| Expression, purification, and characterization of avian Thy-1 from Lec1 mammalian and Tn5 insect cells. | 2004 Feb |
|
| Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. | 2004 Feb 10 |
|
| Identification of endogenous phosphorylation sites of bovine medium and low molecular weight neurofilament proteins by tandem mass spectrometry. | 2004 Feb 24 |
|
| Synthesis of (2S,3S)-3'-fluoroisoleucine. | 2004 Mar 7 |
|
| Alpha-tocopherol pro-vitamins: synthesis, hydrolysis and accumulation in rabbit ear skin. | 2004 Oct 19 |
|
| Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions. | 2004 Sep |
|
| Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate. | 2005 Aug 2 |
|
| The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains. | 2005 Jul 1 |
|
| Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology. | 2005 Sep 21 |
|
| Thermostability and in vitro digestibility of a purified major allergen 2S albumin (Ses i 1) from white sesame seeds (Sesamum indicum L.). | 2005 Sep 25 |
|
| CFSUM1 and CFSUM2 in urine from patients with chronic fatigue syndrome are methodological artefacts. | 2006 Feb |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 20:35:36 UTC 2022
by
admin
on
Fri Dec 16 20:35:36 UTC 2022
|
| Record UNII |
V5PC588N7G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA12CC08
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
||
|
WHO-ATC |
A12CC08
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MAGNESIUM PIDOLATE
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
DBSALT002689
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
CHEMBL397976
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
V5PC588N7G
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
V5PC588N7G
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
14559042
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
116240
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | RxNorm | ||
|
4597
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
263-365-7
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
SUB03045MIG
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY | |||
|
62003-27-4
Created by
admin on Fri Dec 16 20:35:36 UTC 2022 , Edited by admin on Fri Dec 16 20:35:36 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |